Pharming Group N.V. (PHAR) Form 6-K — Oct 22, 2026
Pharming Group announced preliminary unaudited Q3 2026 revenues of approximately US$117.6 million, up about 21% year-on-year from US$97.3 million and above analyst consensus, driven by RUCONEST (US$93.8 million, +14% YoY) and Joenja (US$23.8 million, +58% YoY). Operating expenses of roughly US$74.6 million were in line with the prior-year quarter, which the company attributes to efficient scaling. Pharming tightened its FY2026 revenue guidance to US$380-390 million and lowered expense guidance to US$310-315 million. The company brought forward its full Q3 results and business update from November 5 to October 27, 2026, with a conference call at 13:30 CET/08:30 EDT.
Key figures
- Revenue
- 117600000
- Guidance
- 2026 total revenue tightened to $380M-$390M (from $375M-$395M); total operating expense guidance lowered to $310M-$315M (from $315M-$320M)
- Revenue Yoy
- 21%
- Joenja q3 revenue
- US$23.8 million (+58% YoY)
- Ruconest q3 revenue
- US$93.8 million (+14% YoY, +30% QoQ)
- Q3 2025 total revenue
- US$97.3 million
- Q3 2026 operating expenses
- US$74.6 million
- Apds prevalence per million
- 1.5
- Cvid prevalence per million
- 39
- Falcon trial planned subjects
- 180
- Falcon trial subjects enrolled by end 2026
- 145
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.